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Background: Community-acquired pneumonia (CAP) is more common in patients with COPD 
than in the adult general population, with studies of hospitalized CAP patients consistently 
reporting COPD as a frequent comorbidity. However, despite an increasing recognition of its 
importance, large studies evaluating the incidence patterns over time, risk factors and burden 
of CAP in COPD are currently lacking.
Methods: A retrospective observational study using a large UK-based database of linked 
primary and secondary care records was conducted. Patients with a diagnosis of COPD aged 
$40 years were followed up for 5 years from January 1, 2010. CAP and exacerbation episodes 
were identified from hospital discharge data and primary care coding records, and rates were 
calculated per month, adjusting for mortality, and displayed over time. In addition, baseline 
factors predicting future risk of CAP and hospital admission with CAP were identified.
Results: A total of 14,513 COPD patients were identified: 13.4% (n=1,938) had $1 CAP 
episode, of whom 18.8% suffered from recurrent ($2) CAP. Highest rates of both CAP and 
exacerbations were seen in winter. A greater proportion of frequent, compared to infrequent, 
exacerbators experienced recurrent CAP (5.1% versus 2.0%, respectively, P,0.001); 75.6% of 
CAP episodes were associated with hospital admission compared to 22.1% of exacerbations. 
Older age and increasing grade of airflow limitation were independently associated with increased 
odds of CAP and hospital admission with CAP. Other independent predictors of future CAP 
included lower body mass index, inhaled corticosteroid use, prior frequent exacerbations and 
comorbidities, including ischemic heart disease and diabetes.
Conclusion: CAP in COPD demonstrates clear seasonal patterns, with patient characteristics 
predictive of the odds of future CAP and hospital admission with CAP. Highlighting this burden 
of COPD-associated CAP during the winter period informs us of the likely triggers and the need 
for more effective preventive strategies.
Keywords: COPD exacerbations, exacerbation frequency, community-acquired pneumonia, 
comorbidity
Introduction
Community-acquired pneumonia (CAP) is a major cause of morbidity, mortality and 
health care burden globally.1,2 Certain population groups are more susceptible, particularly 
the elderly and those with chronic conditions such as COPD.3,4 The prevalence of COPD 
increases with age and is estimated to affect ~210 million people globally, and therefore 
this population contributes significantly to the overall disease burden of CAP.5,6
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The clinical course of COPD is interspersed by episodes 
of symptomatic deterioration, termed exacerbations. CAP 
and exacerbations can be difficult to distinguish clinically, 
and there remains no clear consensus on whether they 
represent distinct events or are in fact a continuum. Exac-
erbations are highly seasonal, with increasing rates seen in 
the winter months, adding further to the pressures already 
experienced by overstretched health care providers at this 
time of year.7,8 The winter peak coincides with the increased 
activity of viral infection, and a causal relationship has been 
proposed.9 Although exacerbations are more frequent in 
winter, it is not known whether COPD-associated CAP has 
a similar seasonal pattern. In Europe, hospitalizations due to 
CAP are increasing, with COPD a frequently encountered 
comorbidity.10,11 Reports suggest that patients with COPD 
hospitalized with CAP present with more severe symptoms 
and have longer hospital stays and increased need for ICU 
admission.12–14 CAP is common in the natural history of 
COPD, with a much higher incidence compared to that of 
the adult general population.4 Furthermore, in a UK-based 
audit, 18% of COPD patients requiring hospitalization for 
acute respiratory illness had consolidation evident on chest 
X-ray, diagnostic of CAP.15 Recent reports have highlighted 
an increased risk of CAP associated with inhaled corticos-
teroid (ICS) use in COPD patients, underlining the need for 
stratification of patients for ICS use to include an estimation 
of this risk.16,17 Therefore, COPD-associated CAP is particu-
larly relevant considering the aging global population and 
will have important implications for future antibiotic usage 
and health care resources.
Despite the greater incidence of CAP in COPD compared 
to the adult general population, it remains a relatively infre-
quent event compared to exacerbations. Consequently, the 
true burden of CAP in COPD has been largely overlooked 
and limited to predominantly cross-sectional analyses of hos-
pitalized patients.18,19 Analysis of large population databases 
can provide a “real-world” perspective of incidence patterns, 
health care usage and risk factors of CAP in COPD and, thus, 
an understanding of the likely triggers, susceptibilities and 
socioeconomic burden of what still remains a poorly under-
stood event in the natural history of many COPD patients. 
This is key to guiding future, targeted research, focusing on 
preventative strategies in vulnerable patient groups.
Linked primary and secondary health care records have 
the potential to improve the accuracy of disease incidence 
estimates compared to stand-alone records.20 Therefore, using 
the Hampshire Health Record Analytical (HHRA) data-
base, an anonymized database of linked health care records 
covering ~75% of primary care practices in Hampshire, 
Southern England, we sought to describe the seasonal 
patterns, hospital admissions and risk factors for CAP, among 
patients with COPD.
Methods
study design and population
A retrospective, observational cohort design was used. 
Patients were defined as having COPD and eligible for inclu-
sion if they had $1 COPD-specific Read code (standard UK 
classification of clinical terms for electronic coding)21 in their 
primary care record at any time prior to January 1, 2010, and 
were aged $40 years at the start of the study. Follow-up ran 
for 5 years from January 1, 2010, until December 31, 2014.
The HHRA database was used for data collection (Sup-
plementary material). Briefly, it represents a large electronic 
database of individual patient-anonymized primary and 
secondary care records, providing a single source of linked 
routine health data for patients living in Hampshire, Southern 
England. At the time of the study, the HHRA contained 
records covering ~1.4 million patients from .140 primary 
care practices.
Use of the HHRA database for research is regulated 
by the Hampshire Health Record Information Governance 
Group (HHRIGG) and National Health Service (NHS) South, 
Central and West Commissioning Support Unit. NHS data 
systems entitle patients to opt-out of consenting to storage 
and use of personal information for analytical purposes. 
Furthermore, as the HHRA data are anonymized, it is not pos-
sible to identify patients; as such, and as confirmed by local 
research governance (University of Southampton Research, 
Integrity and Governance Team), formal ethical approval 
and written informed consent from all participants were not 
required for this study.
Demographics and clinical factors
Data were collected on sex, age, weight, height, body mass 
index (BMI) and disease severity by Global Initiative for 
Obstructive Lung Disease (GOLD) stage at the most recently 
recorded time point prior to the study start date, within a pre-
assigned limit of 2 years. Comorbidities were identified using 
Read code lists and included as present if recorded at any 
time prior to the study start. Usage of concurrent therapies 
for COPD was included if $1 prescription was evident in the 
6 months prior to the study start, with the exception of oral 
corticosteroids (OCSs), where frequent use was defined as $4 
prescriptions in the year prior to the study start. Code lists for 
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seasonality, risk factors and burden of CaP in COPD patients
COPD-associated CaP
CAP episodes were identified either from a relevant Interna-
tional Classification of Diseases Version 10 (ICD-10) code 
in the primary diagnostic position following an inpatient 
hospital stay or emergency department (ED) attendance or 
from a physician Read-coded diagnosis of CAP. In order 
to avoid capturing multiple-coded events for one illness as 
different episodes, single-coded CAP events were grouped 
into clusters. Clusters were defined as the number of CAP 
events occurring within a continuous 70-day period, with the 
date of the first event regarded as the index date.4 A period 
of at least 2 event-free weeks following CAP episodes was 
required in order to avoid labeling prolonged recording of 
events for the same illness, as new episodes.
COPD exacerbations
Exacerbations were defined as either, 1) a physician Read-
coded diagnosis of exacerbation, 2) the prescription of specific 
antibiotics or OCS on the same day or up to 7 days before 
or after a COPD diagnostic or symptom Read code, or 3) a 
relevant respiratory ICD-10 code in the primary or secondary 
diagnostic positions, following an inpatient hospital stay or ED 
attendance. A continuous 21-day period defined an episode, 
with 2 event-free weeks required to separate exacerbations.
seasonality
The month of the index event (CAP or exacerbation) date was 
taken as the month of episode occurrence. Winter was defined 
as December to February and summer as June to August.
statistical analysis
Analyses were performed using SPSS version 22. CAP and 
exacerbation rates were calculated per month, adjusting for 
mortality, and displayed over time. Categorical variables are 
presented as number (percentage). Chi-square tests were used 
to compare data between groups with and without a diagno-
sis of CAP. Multivariate logistic regression was then used 
to identify adjusted odds ratios (ORs) and 95% confidence 
intervals (95% CIs) for having $1 CAP episode versus none, 
in patients with complete data, who either survived until the 
end of the observation period or died following CAP. Covari-
ates reaching significance from the bivariate analysis were 
included in the multivariate model. To identify risk factors 
for hospital admission during CAP, we used STATA to 
conduct conditional logistic regression, treating subject as a 
random effect. This accounted for the over-representation of 
some patients (ie, those experiencing .1 CAP). A P-value 
of ,0.05 was considered statistically significant.
Results
Population characteristics
The study cohort consisted of 14,513 patients with a diagnosis 
of COPD. The mean ± standard deviation (SD) age at the 
start of the study period was 70.3±10.8 years; 53.6% were 
male and 33.5% were current smokers (Table 1). Of the 
cohort in which lung function data were available (n=10,358), 
mean ± SD forced expiratory volume in 1 second (FEV
1
) 
%predicted was 59.5±19.8. Overall, exacerbations were 
more prevalent than CAP. The incidence rate for CAP was 
37.6 per 1,000 person-years, with 13.4% (n=1,938) experi-
encing at least one CAP, and of these, 18.8% (n=364) had 
more than one.
seasonality of CaP, exacerbations and 
hospital admissions
Figure 1A and B displays the total monthly rates of CAP and 
exacerbations across 5 years, while Figure 1C and D displays 
the rates averaged into 1 calendar year. A clear seasonal 
pattern is evident with highest rates of CAP in the winter, 
especially December, compared to other periods of the year. 
Median monthly CAP rates were 4.0 per 1,000 person-months 
in winter versus 2.8 in summer (P=0.003). Similarly, for 
exacerbations, higher rates occurred in winter, with lower 
rates in summer (83.6 versus 60.5 per 1,000 person-months, 
respectively, P,0.001).
A total of 2,413 CAP episodes were identified over 
5 years. Trends in hospital admissions associated with CAP 
closely followed the seasonal distribution of total CAP epi-
sodes, with 75.6% of CAP associated with hospital admis-
sion, compared to only 22.1% of exacerbations.
risk factors for CaP
Using multivariate logistic regression modeling and con-
trolling for potential confounders, factors independently 
predicting CAP risk were identified (Table 2). The odds of 
experiencing CAP increased with age, with patients aged 
60–79 and $80 years having higher odds than those aged 
40–59 years (OR 1.67, 95% CI 1.30–2.16 and OR 4.10, 
95% CI 3.05–5.49, respectively). BMI was also strongly 
associated with the odds of CAP, with those underweight 
having higher odds (OR 1.82, 95% CI 1.27–2.62) than 
those of normal weight. Conversely, the odds of CAP in 
overweight and obese patients was ~30% lower (OR 0.73, 
95% CI 0.61–0.87 and OR 0.70, 95% CI 0.58–0.85, respec-
tively) than that in patients of normal weight. Increasing 
grade of airflow limitation was associated with higher odds 
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times the odds compared to GOLD stage I (OR 2.86, 95% 
CI 2.00–4.09).
Additional factors independently associated with 
increased odds of CAP were a prior history of CAP and 
comorbid diseases, including ischemic heart disease (IHD), 
diabetes and chronic kidney disease (CKD).
exacerbation frequency and CaP risk
A history of frequent exacerbations, defined as $2 exac-
erbations in the year prior to the study start date, appears 
to be predictive of future CAP. Frequent exacerbators had 
almost 30% higher odds of having CAP over the study 
period (OR 1.29, 95% CI 1.08–1.54), compared to infrequent 
Table 1 Patient demographics and baseline clinical characteristics of the total COPD cohort, by presence or absence of a CaP 
diagnosis over the 5-year study period
Characteristic Total No CAP $1 CAP P-value
number of patients 14,513 12,575 (86.6) 1,938 (13.4)
sex (male) 7,775 (53.6) 6,707 (53.3) 1,068 (55.1) 0.145
age (years) ,0.001
40–59 2,347 (16.2) 2,171 (17.3) 176 (9.1)
60–79 9,044 (62.3) 7,839 (63.1) 1,105 (57.0)
$80 3,122 (21.5) 2,465 (19.6) 657 (33.9)
smoking status (n=12,972) 0.027
Current 4,859 (33.5) 4,255 (37.8) 604 (35.1)
ex/never 8,113 (55.9) 6,994 (62.2) 1,119 (64.9)
BMI, kg/m2 (n=9,235) ,0.001
Underweight (,18.5) 340 (3.7) 275 (3.4) 65 (5.5)
normal weight (18.5–24.9) 2,911 (31.5) 2,483 (30.9) 428 (36.1)
Overweight (25.0–29.9) 3,247 (35.2) 2,874 (35.7) 373 (31.4)
Obese ($30) 2,737 (29.6) 2,416 (30.0) 321 (27.0)
Prior CaP 358 (2.5) 253 (2.0) 105 (5.4) ,0.001
exacerbation frequency ,0.001
Frequent ($2 per year) 2,496 (17.2) 2,004 (15.9) 492 (25.4)
Infrequent (,2 per year) 12,017 (82.8) 10,571 (84.1) 1,446 (74.6)
Pharmacotherapy
ICs use 7,806 (53.8) 6,348 (50.5) 1,112 (57.9) ,0.001
Frequent OCs use 1,202 (8.3) 925 (7.4) 277 (14.3) ,0.001
laBa use 6,376 (43.9) 5,353 (42.6) 1,023 (52.8) ,0.001
laMa use 4,046 (27.9) 3,323 (26.4) 723 (37.3) ,0.001
Prior pneumococcal vaccine 4,790 (33) 4,167 (33.1) 623 (32.1) 0.388
Comorbidity
IhD 2,853 (19.7) 2,347 (18.7) 506 (26.1) ,0.001
heart failure 931 (6.4) 739 (5.9) 192 (9.9) ,0.001
hypertension 6,043 (41.6) 5,146 (40.9) 897 (46.3) ,0.001
Diabetes mellitus 1,978 (13.6) 1,622 (12.9) 356 (18.4) ,0.001
Peripheral vascular disease 852 (5.9) 692 (5.5) 160 (8.3) ,0.001
hyperlipidemia 2,514 (17.5) 2,203 (17.5) 338 (17.4) 0.933
Cerebrovascular disease 1,397 (9.6) 1,115 (8.9) 282 (14.6) ,0.001
Dementia 306 (2.1) 245 (1.9) 61 (3.1) 0.001
asthma 6,989 (48.2) 5,982 (47.6) 1,007 (52.0) ,0.001
gOrD 1,423 (9.8) 1,198 (9.5) 225 (11.6) 0.004
anxiety or depression 5,380 (37.1) 4,643 (36.9) 737 (38.0) 0.348
Osteoporosis 955 (6.6) 780 (6.2) 175 (9.0) ,0.001
CKD 2,263 (15.6) 1,836 (14.6) 427 (22.0) ,0.001
Connective tissue disease 350 (2.4) 280 (2.2) 70 (3.6) ,0.001
gOlD staging (n=10,358) ,0.001
I 1,524 (14.7) 1,387 (15.4) 137 (10.0)
II 5,396 (52.1) 4,795 (53.3) 601 (43.9)
III 2,803 (27.1) 2,299 (25.6) 504 (36.8)
IV 635 (6.1) 509 (5.7) 126 (9.2)
Notes: Data are presented as frequencies (%). P-values from chi-square test.
Abbreviations: BMI, body mass index; CaP, community-acquired pneumonia; CKD, chronic kidney disease; gOlD, global Initiative for Obstructive lung Disease; gOrD, 
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seasonality, risk factors and burden of CaP in COPD patients
exacerbators. In addition, a greater proportion of frequent 
exacerbators experienced recurrent CAP over 5 years, 
compared with infrequent exacerbators (5.1% versus 2.0%, 
P,0.001) (Figure 2).
risk factors for hospital admission 
associated with CaP
Conditional logistic regression, accounting for subject effect, 
was used to examine associations between patient charac-
teristics and the odds of hospital admission during CAP 
episodes (n patients =1,368, n CAP =1,721). Increasing age 
and grade of airflow limitation were independently associ-
ated with increased odds of hospital admission during CAP 
(Table 3).
all-cause mortality
A total of 2,877 deaths occurred over the 5-year study period. 
All-cause mortality followed a similar seasonal distribution 
to CAP and exacerbations (Figure 3); 880 (30.6%) deaths 
occurred in winter compared to 602 (20.9%) in summer.
































































Figure 1 seasonality of CaP and exacerbations.
Notes: Total monthly rates and rate of hospital admission for CaP (A) and exacerbations (B) in COPD over 5 years. (C and D) represent the data for CaP and 
exacerbations, respectively, averaged over 1 calendar year and displayed as the median monthly rate.
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This is the first population-based study showing the seasonal 
trends of CAP and exacerbations among people with COPD, 
using linked primary and secondary care data sources. The 
incidence rate of 37.6 CAP cases per 1,000 person-years 
compares to that of 22.4 reported by Mullerova et al4 in 
COPD patients and 7.99 reported by Millett et al3 of adults 
aged $65 years, not limited to COPD.
A total of 13.4% of our study population had CAP over 
5 years, with almost a fifth of these having more than one 
episode. CAP occurrence is to some extent a predictable 
phenomenon and tracks with exacerbation frequency. More-
over, there are potentially modifiable factors such as BMI 
and concurrent medication use, which could form the basis 
Table 2 adjusted Ors and 95% CIs for predictors of 5-year 
CaP risk
n=6,805 OR 95% CI P-value
sex
Female reference
Male 1.182 1.015–1.376 0.031
age (years)
40–59 reference
60–79 1.674 1.296–2.161 ,0.001
$80 4.096 3.053–5.494 ,0.001
smoking status
ex/never reference
Current 1.316 1.121–1.544 0.001
BMI, kg/m2
Underweight (,18.5) 1.823 1.267–2.624 0.001
normal weight (18.5–24.9) reference
Overweight (25–29.9) 0.729 0.610–0.872 0.001
Obese ($30) 0.701 0.576–0.853 ,0.001
Prior CaP 2.228 1.453–3.415 ,0.001
exacerbation frequency
Infrequent (,2 per year) reference
Frequent ($2 per year) 1.291 1.080–1.543 0.005
Pharmacotherapy
ICs use 1.229 1.001–1.508 0.049
Frequent OCs use 1.934 1.539–2.431 ,0.001
laBa use 1.136 0.936–1.379 0.196
laMa use 1.398 1.199–1.628 ,0.001
Comorbidities
IhD 1.312 1.102–1.562 0.002
heart failure 1.415 1.065–1.881 0.017
hypertension 1.081 0.929–1.258 0.315
Diabetes mellitus 1.736 1.438–2.097 ,0.001
Peripheral vascular disease 1.364 1.044–1.784 0.023
Cerebrovascular disease 1.325 1.050–1.672 0.018
Dementia 2.219 1.271–3.877 0.005
asthma 1.049 0.901–1.220 0.538
gOrD 1.179 0.948–1.467 0.138
CKD 1.322 1.093–1.600 0.004
Osteoporosis 1.173 0.882–1.559 0.273
Connective tissue disease 1.688 1.110–2.565 0.014
gOlD stage
I reference
II 1.296 1.018–1.649 0.035
III 2.239 1.735–2.891 ,0.001
IV 2.861 2.003–4.085 ,0.001
Notes: Multivariate logistic regression model of 6,805 patients with complete data, 
who either survived until the end of the 5-year observation period or died during 
the observation period following a CaP episode and were not lost to follow-up. For 
comorbidities and pharmacotherapy, not having the comorbidity and not using the 
drug were taken as the reference.
Abbreviations: BMI, body mass index; CaP, community-acquired pneumonia; CI, 
confidence interval; CKD, chronic kidney disease; GORD, gastroesophageal reflux 
disease; ICs, inhaled corticosteroid; IhD, ischemic heart disease; laBa, long-acting 
beta-agonist; laMa, long-acting muscarinic antagonist; gOlD, global Initiative for 




















Figure 2 associations between CaP frequency and the frequent exacerbator 
phenotype over 5 years.
Notes: P-values from chi-square test. *P,0.001.
Abbreviation: CaP, community-acquired pneumonia.
Table 3 adjusted Or and 95% CI for hospital admission with 
CaP
n=1,721 OR 95% CI P-value
sex
Female reference
Male 1.104 0.779–1.565 0.576
age (years)
40–59 reference
60–79 1.875 1.050–3.348 0.034
$80 4.559 2.341–8.878 ,0.001
ICs use 1.428 0.973–2.097 0.069
Prior CaP 0.549 0.255–1.182 0.126
exacerbation frequency
Infrequent (,2 per year) reference
Frequent ($2 per year) 1.143 0.780–1.676 0.494
gOlD
I reference
II 2.325 1.307–4.134 0.004
III 2.784 1.530–5.068 0.001
IV 4.536 1.960–10.501 ,0.001
Note: Multivariate conditional logistic regression model, including the patient 
as a random effect, of 1,721 CaP episodes (occurring in 1,368 patients) with 
complete data.
Abbreviations: CAP, community-acquired pneumonia; CI, confidence interval; 
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seasonality, risk factors and burden of CaP in COPD patients
of targeted risk-reducing strategies. Greater understanding 
of the underlying mechanisms is therefore required to 
establish why some patients are more susceptible to CAP 
than others.
CAP occurred more commonly in the winter, compared 
to other times of the year. Similarly for exacerbations, and in 
line with findings from the Towards a Revolution in COPD 
Health (TORCH) study, a clear and consistent seasonal 
pattern from year to year was seen.7 Importantly, our study 
population differs from the TORCH study, as it benefits from 
providing a true insight into real-world population trends 
across all severity of COPD, as compared to a highly selected 
patient cohort with more severe disease.
The majority of reports to date suggest that CAP in COPD 
is caused primarily by bacterial infection.18,22,23 However, 
the microbiological profile of CAP in adult patients without 
COPD has a proven seasonal basis with an important role 
attributed to viral infection.24,25 Holter et al24 demonstrated 
that CAP occurring in the winter and spring is associated 
with a greater frequency of bacterial–viral co-infection, 
supporting the results from an earlier study by Lieberman 
et al,25 showing greater frequencies of respiratory viral infec-
tion ascribed to CAP in these seasons. There is also a large 
body of evidence supporting the role of influenza infection 
and secondary bacterial pneumonia;26 yet, this finding is not 
apparent in reports for CAP in COPD. A separate analysis 
of our data (not shown) for each individual influenza sea-
son during the 5-year period indicated no strong associa-
tions between reduced CAP rates and receipt of influenza 
vaccination. Certainly, our data show a greater rate of CAP 
in the winter compared to other times of the year, suggest-
ing that respiratory viral infection may have an important 
causative role. Indeed, environmental factors, notably lower 
temperatures and changes in relative humidity during winter, 
may favor the survival of respiratory viruses and increase 
host susceptibility to infection.9 It was not until relatively 
recently that viral infection and cold symptoms, a marker 
of putative viral infection, were established as important 
determinants of COPD exacerbations, leading to worsen-
ing symptoms and prolonged recovery.27,28 With the proven 
seasonality of exacerbations and now CAP in COPD, viral 
infection must be considered as a key early determinant in 
the sequence of events leading to both exacerbations and 
CAP in COPD patients.
Like other reports, we found that increasing age, poorer 
lung function, lower BMI and comorbid disease, particularly 
IHD, diabetes and CKD, were all independently associ-
ated with future CAP risk.4,16 It is already known that the 
elderly, especially those aged .65 years, are particularly 
susceptible to developing CAP.29 The mechanisms are 
complex, but age-influenced immune system dysregulation, 
predisposing to infection risk is likely to be of importance. 
On a population-based level, physicians may be more likely 
to diagnose respiratory infection in older, frailer patients, 
and yet, we found no observed influence of age on the risk 
of exacerbation (data not shown). Like previous studies, 
we show the association between lower BMI and increased 
CAP risk and higher BMI with reduced risk, compared to 
normal weight patients.4,16 This perceived protective effect 
of a higher BMI has also been reported previously in studies 
not limited to COPD patients.30 Yet, despite the underlying 
reasons remaining unclear, it could still provide a potentially 
useful target for risk-reducing interventions.
A susceptibility to frequent exacerbations is now a well-
established COPD phenotype and has been shown to be 
fairly consistent over time.31 Frequent exacerbators are more 
susceptible to viral infection and have higher levels of airway 
inflammation at stable state, both proposed as possible under-
lying mechanisms.32 We have established prior exacerbation 
frequency as an independent risk factor for CAP, with an 
increased proportion of frequent exacerbators experiencing 
recurrent CAP. However, a prior history of frequent exacer-
bations does not appear to influence the likelihood of more 
severe (ie, hospitalized) CAP events. Furthermore, and in line 
with a previous report, we show that a prior history of CAP 
is a risk factor for future CAP.4 Whether the mechanisms 
underlying exacerbation frequency and CAP susceptibility 
are the same requires further research.
As anticipated, our study re-confirms ICS use as an inde-
pendent risk factor for future CAP, with a further trend evident 
between ICS use and increased odds of hospital admission 
associated with CAP. Interestingly, long-acting muscarinic 














Figure 3 all-cause mortality rate over 5 years, averaged into 1 calendar year and 
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antagonist (LAMA) use was independently associated with 
increased odds of CAP. Published data have shown that in 
COPD patients with severe disease (FEV
1
 ,50% predicted), 
LAMA use appears to confer less risk of CAP than ICS use.17 
However, data pertaining to CAP risk with LAMA use in 
large population analyses of COPD patients and importantly 
across all disease severities are currently lacking.
The burden of respiratory-related health care utilization 
and hospital attendances, especially for COPD and CAP, 
is substantial, with the winter period being particularly 
pressured.33,34 In line with an increased rate of CAP in win-
ter, we have shown that the number of hospital admissions 
with CAP also increases substantially, proportionally much 
more so than with exacerbations. Patients who required 
hospital admission were older and had greater severity of 
underlying COPD, representing a vulnerable group and those 
most likely to impose a greater resource burden.35 More 
than 75% of CAP episodes were associated with hospital 
admission, which is much higher than most reports for the 
adult general population36,37 and probably indicates a lower 
threshold for admitting COPD patients to hospital, or a 
manifestation of more severe symptoms. Regardless, with 
the aging global population and increasing prevalence of 
COPD, CAP will become a growing future problem in this 
chronic disease group.
We acknowledge that this study has limitations. We 
were unable to validate CAP diagnoses with independent 
assessment of chest X-ray findings, as this was a large 
population database containing anonymized data in which 
radiological features were assessed by the attending phy-
sician. However, Skull et al38 have reported that ICD-10 
codes can be a valid method of retrospectively identifying 
CAP from medical records. A large proportion of CAP in 
our study was associated with hospital admission and based 
on hospital discharge diagnoses, and therefore it is highly 
likely that a chest X-ray was performed in these cases, 
confirming the diagnosis.
With regard to our study population, we included patients 
with a Read-coded diagnosis of COPD and did not require 
spirometric confirmation for study inclusion. However, this 
method has been shown to accurately identify COPD patients 
from UK primary care records with spirometry only margin-
ally improving the accuracy.39
Conclusion
Like exacerbations, COPD-associated CAP is highly sea-
sonal, with an increased burden observed over winter. Despite 
occurring less frequently in the natural history of COPD than 
exacerbations, its relative impact on health care utilization 
is considerable, with the most vulnerable patients often at 
greatest risk of both events. In addition, establishing com-
mon risk factors may allow for a prospective estimation of 
a patient’s risk of future CAP, aiding clinicians in treatment 
and management decisions. Studies, focusing on preventative 
strategies such as interventions to reduce risk and improve 
outcomes, including nutritional interventions, treatment 
stratification and new and improved vaccination programs, 
are key to tackling the increasing future burden of CAP in 
at-risk patients, such as those with COPD.
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Methods – data source
hampshire health record (hhr) and electronic 
health care data sets
The HHR is an electronic shared care record for people 
living in Hampshire that provides a single source of linked 
routine health data for individual patients, collected in “real 
time”, and links data from general practitioner practices and 
hospitals and recently includes some data from social care. 
It is able to combine data from many different IT systems. It is 
not part of the National Summary Care Record but rather is 
an arrangement local to Hampshire, storing data from a wide 
range of practices that have “opted in” to the data-sharing 
scheme. The HHR is used by clinicians to share information 
and aid clinical decision-making and is currently supported 
with data supplied by many organizations in the South of 
England, including local primary care practices and providers 
of secondary, community and social care.
hampshire health record analytical (hhra) 
database
The HHRA database is a separate electronic database cre-
ated for research and analysis to support health improvement 
and planning. At the time of this study, it included data 
from .140 practices across Hampshire, covering ~1.4 million 
patients. It shares some of the health data contained within 
the HHR but in anonymized form to protect patients’ iden-
tity. The HHR and the HHRA are hosted and maintained 
by NHS South, Central and West Commissioning Support 
Unit (CSU). The Governance body is the HHR Information 
Governance Group (HHRIGG), which ensures the security 
and confidentiality of the HHR and HHRA and considers 
issues of data integration or data sharing. Linked data con-
tained within HHRA includes:
• Primary care data: 
Coded clinical entries made during routine patient care
• Secondary care data:
Radiology and pathology data
Inpatient, outpatient and emergency department (ED) 
secondary uses service (SUS) data.
Primary care coding within the HHRA uses Read codes, 
which are the standard clinical terminology system used in 
primary care in the UK. The Read code system comprises a 
detailed hierarchy of codes describing diagnoses, symptoms, 
signs, processes of care, investigations, administrative items, 
procedures and medication; 90% of UK practices use Read 
version 2 (V2) codes, which were used for the purpose of 
data capture for this study.
The HHRA allows full access to coded hospital activ-
ity data from SUS, thereby allowing quantification of 
respiratory-related hospital-based health care use to a much 
greater extent than is possible through databases accessing 
primary care data alone. The hospital data are the same as that 
used in contracting, accounting and NHS reporting processes, 
so high quality is assured.
The secondary care information used was Payment by 
Results data drawn from the SUS, which involves many 
quality control/validation processes applied at national 
level. For primary care information, basic data cleaning had 
already been performed within the NHS environment before 
data were imported into the HHR and HHRA. For this study, 
data cleaning involved excluding from the data set duplicated 
records and assessments with null and zero values and values 
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